Alison Bratzell

“Just going back to the unity futility decision, I guess, could you talk to, you know, do you have a sense of whether that outcome was specific to Sjogren's biology, its trial design, something else, and just, does that change your confidence in pursuing other rheumatology indications like systemic sclerosis?”

“Just a follow-up on OcularMG and the potential for early treatment with VivGuard to prevent progression to generalize that these um is that something you're able to capture in part b of the oculus trial or just how long of a follow-up do you need to to confidently be able to make that claim um if there's any more…”